Suppr超能文献

非诺贝特改善高脂饮食诱导的小鼠全身和视网膜炎症,并调节肠道微生物群。

Fenofibrate Ameliorated Systemic and Retinal Inflammation and Modulated Gut Microbiota in High-Fat Diet-Induced Mice.

机构信息

Aier School of Ophthalmology, Central South University, Changsha, China.

University of Science and Technology of China, Suzhou Institute of Biomedical Engineering and Technology, Suzhou, China.

出版信息

Front Cell Infect Microbiol. 2022 Jun 2;12:839592. doi: 10.3389/fcimb.2022.839592. eCollection 2022.

Abstract

Fenofibrate, as a lipid-lowering drug, has been reported to have a protective effect on the retina independent with plasma lipid levels. This study aimed to investigate that the ameliorative effects of fenofibrate on systemic and retinal inflammation, as well as gut microbiota dysbiosis in high-fat diet (HFD)-induced mice. C57BL/6J mice were randomly allocated into four groups: standard diet (SD) group; HFD group; SD plus fenofibrate (SD_ Fe) group; HFD plus fenofibrate (HFD_ Fe) group. After successfully establishing models (5 months), indicators associated with lipid, gut barrier, inflammation and gut microbiota were investigated. Our results showed that supplementing the HFD with fenofibrate decreased body weight gain, alleviated dyslipidemia and reversed the downregulation of short-chain fatty acid (SCFAs) in serum, retina and feces. Fenofibrate ameliorated intestinal barrier function damage in HFD-induced mice. Fenofibrate coadministration inhibited the levels of inflammatory factor and lipopolysaccharide (LPS) in the serum and attenuated inflammatory response in the retina of HFD-induced mice. Systemic LPS was positively correlated with a series of inflammatory factors in serum and retina, respectively. Fenofibrate supplementation down-regulated the abundances of LPS-associated bacteria in HFD mice, including and at the phylum level, at the family level, as well as , , , and at the genus level. However, fenofibrate treatment up-regulated the abundances of SCFA-associated bacteria in HFD mice, including at the phylum level, at the family level, as well as , , and at the genus level. In conclusion, our results confirmed fenofibrate could attenuate HFD-induced systemic and retinal inflammation, accompanying with restoration of intestinal barrier damage and modulation of gut microbiota/metabolites. This work provided an explanation for the ameliorative effects of fenofibrate on HFD-induced systemic and retinal inflammation might be partially related with the modulation of gut microbiota and its metabolites.

摘要

非诺贝特作为一种降脂药物,已被报道具有独立于血浆脂质水平的对视网膜的保护作用。本研究旨在探讨非诺贝特对高脂肪饮食(HFD)诱导的小鼠全身和视网膜炎症以及肠道微生物失调的改善作用。C57BL/6J 小鼠被随机分为四组:标准饮食(SD)组;HFD 组;SD 加非诺贝特(SD_Fe)组;HFD 加非诺贝特(HFD_Fe)组。在成功建立模型(5 个月)后,研究了与脂质、肠道屏障、炎症和肠道微生物相关的指标。我们的结果表明,在 HFD 中补充非诺贝特可降低体重增加,缓解血脂异常,并逆转血清、视网膜和粪便中短链脂肪酸(SCFA)的下调。非诺贝特改善了 HFD 诱导的小鼠肠道屏障功能损伤。非诺贝特共给药抑制了血清和 HFD 诱导的小鼠视网膜中炎症因子和脂多糖(LPS)的水平,并减轻了炎症反应。全身 LPS 与血清和视网膜中的一系列炎症因子分别呈正相关。非诺贝特补充剂下调了 HFD 小鼠中与 LPS 相关的细菌丰度,包括门水平的 和 ,科水平的 ,以及属水平的 、 、 、 和 。然而,非诺贝特处理上调了 HFD 小鼠中与 SCFA 相关的细菌丰度,包括门水平的 ,科水平的 ,以及属水平的 、 、 、 和 。总之,我们的结果证实,非诺贝特可减轻 HFD 诱导的全身和视网膜炎症,同时恢复肠道屏障损伤并调节肠道微生物群/代谢物。这项工作为非诺贝特改善 HFD 诱导的全身和视网膜炎症的作用机制提供了一种解释,可能部分与肠道微生物群及其代谢物的调节有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d23e/9201033/e3c71adf5b27/fcimb-12-839592-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验